Feb 24, 2026 04:01PM
Feb 11, 2026 04:01PM
Jan 26, 2026 08:30AM
Jan 26, 2026 08:30AM
Jan 21, 2026 04:01PM
Jan 15, 2026 08:32AM
Jan 15, 2026 08:30AM Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Jan 5, 2026 04:01PM
Dec 22, 2025 04:05PM
Dec 22, 2025 04:05PM
Dec 21, 2025 08:00PM
Dec 16, 2025 04:01PM
Dec 9, 2025 04:01PM
Nov 20, 2025 08:30AM Neurocrine study highlights differences between tardive dyskinesia drugs
Nov 20, 2025 08:30AM
Nov 16, 2025 03:00PM
Nov 11, 2025 04:01PM
Nov 10, 2025 04:06PM
Nov 10, 2025 04:05PM
Oct 28, 2025 04:01PM
Oct 17, 2025 08:30AM Neurocrine shares data on INGREZZA 40 mg treatment for tardive dyskinesia
Oct 17, 2025 08:30AM
Oct 7, 2025 04:01PM
Oct 6, 2025 04:05PM
Oct 6, 2025 04:05PM
Oct 6, 2025 08:31AM
Oct 6, 2025 08:30AM
Sep 23, 2025 08:30AM Neurocrine shows INGREZZA achieved tardive dyskinesia remission in 58% of patients
Sep 23, 2025 08:30AM
Sep 22, 2025 08:31AM
Sep 22, 2025 08:30AM
Sep 16, 2025 04:05PM
Sep 16, 2025 04:05PM
Aug 26, 2025 04:01PM
Aug 6, 2025 04:01PM Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Jul 30, 2025 04:01PM
Jul 15, 2025 08:31AM
Jul 15, 2025 08:30AM
Jul 14, 2025 04:36PM
Jul 14, 2025 04:35PM
Jul 14, 2025 08:31AM
Jul 14, 2025 08:30AM Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Jul 9, 2025 04:01PM
Jul 7, 2025 07:04AM
Jun 30, 2025 04:05PM
Jun 27, 2025 08:31AM
Jun 27, 2025 08:30AM
Jun 20, 2025 08:31AM
Jun 20, 2025 08:30AM Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskine
Jun 9, 2025 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All